Unique ID issued by UMIN | UMIN000004259 |
---|---|
Receipt number | R000005110 |
Scientific Title | Comparative study for glycemic control and adherence when adding DPP-4 inhibitor alogliptin to patients with type 2 diabetes who had been treated with three times administration of alpha-glucosidase inhibitors but still in poor glycemic control by maintaining, reducing, or stopping the administration of alpha-glucosidase inhibitors. |
Date of disclosure of the study information | 2010/10/01 |
Last modified on | 2010/09/24 12:39:36 |
Comparative study for glycemic control and adherence when adding DPP-4 inhibitor alogliptin to patients with type 2 diabetes who had been treated with three times administration of alpha-glucosidase inhibitors but still in poor glycemic control by maintaining, reducing, or stopping the administration of alpha-glucosidase inhibitors.
alpha-GI0,1,2,3+alogliptin
Comparative study for glycemic control and adherence when adding DPP-4 inhibitor alogliptin to patients with type 2 diabetes who had been treated with three times administration of alpha-glucosidase inhibitors but still in poor glycemic control by maintaining, reducing, or stopping the administration of alpha-glucosidase inhibitors.
alpha-GI0,1,2,3+alogliptin
Japan |
Type 2 Diabetes
Endocrinology and Metabolism |
Others
NO
We compare glycemic control and adherence when adding 25 mg of DPP-4 inhibitor alogliptin to patients with type 2 diabetes who had been treated with three times administration of alpha-glucosidase inhibitors but still in poor glycemic control by maintaining, reducing (twice or once), or stopping the administration of alpha-glucosidase inhibitors.
Efficacy
Confirmatory
Pragmatic
HbA1c, glycoalbumin
Body weight, adherence
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Dose comparison
Numbered container method
4
Treatment
Medicine |
Taking alogliptin only
Taking alpha-GI once a day in addition to alogliptin
Taking alpha-GI twice a day in addition to alogliptin
Taking alpha-GI thrice a day in addition to alogliptin
20 | years-old | <= |
90 | years-old | > |
Male and Female
1.Type 2 Diabetic patients
2.Patients who are taking alpha-GI thrice a day.
3.HbA1c <JDS> level at baseline 6.5-9.0%
4.Subjects who provided written informed consent.
1. Patients who are receiving insulin therapy.
2. Patients who are taking anti-diabetic medicines other than alpha-GI
3. Patients who have a severe hepatic dysfunction.
4. Patients who have a severe renal dysfunction
5. Patients whose doctor in charge judges as inappropriate for the inclusion
120
1st name | |
Middle name | |
Last name | Yasuo Terauchi |
Graduate School of Medicine, Yokohama City University
Department of Endocrinology and Metabolism
3-9 Fukuura, Kanazawa-ku, Yokohama
045-787-2639
1st name | |
Middle name | |
Last name | Kiyomi Masuda |
Graduate School of Medicine, Yokohama City University
Department of Endocrinology and Metabolism
3-9 Fukuura, Kanazawa-ku, Yokohama
045-787-2639
t086051a@yokohama-cu.ac.jp
Graduate School of Medicine, Yokohama City University
Graduate School of Medicine, Yokohama City University
Self funding
None
None
NO
横浜市立大学附属病院(神奈川県)
2010 | Year | 10 | Month | 01 | Day |
Unpublished
Enrolling by invitation
2010 | Year | 09 | Month | 03 | Day |
2010 | Year | 10 | Month | 01 | Day |
2014 | Year | 09 | Month | 01 | Day |
2014 | Year | 09 | Month | 01 | Day |
2014 | Year | 09 | Month | 01 | Day |
2014 | Year | 09 | Month | 01 | Day |
2010 | Year | 09 | Month | 24 | Day |
2010 | Year | 09 | Month | 24 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005110
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |